ORI
STML

Oak Ridge Investments’s Stemline Therapeutics, Inc. STML Stock Holding History

Oak Ridge Investments’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-36,208
Closed -$310K – 154
2017
Q1 		$310K Buy
36,208
+2,055
+6% +$18.7K 0.01% 139
2016
Q4 		$365K Buy
34,153
+21,357
+167% +$258K 0.01% 137
2016
Q3 		$139K Buy
12,796
+2,663
+26% +$21.7K ﹤0.01% 143
2016
Q2 		$69K Hold
10,133
– – ﹤0.01% 140
2016
Q1 		$47K Sell
10,133
-142
-1% -$694 ﹤0.01% 136
2015
Q4 		$65K Sell
10,275
-3,366
-25% -$27.3K ﹤0.01% 142
2015
Q3 		$120K Hold
13,641
– – ﹤0.01% 142
2015
Q2 		$161K Hold
13,641
– – ﹤0.01% 143
2015
Q1 		$197K Buy
13,641
+870
+7% +$13.3K ﹤0.01% 146
2014
Q4 		$218K Sell
12,771
-1,257
-9% -$18.1K 0.01% 142
2014
Q3 		$175K Buy
+14,028
New +$173K ﹤0.01% 143

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oak Ridge Investments's STML Position: Q2 2017 in Review

Oak Ridge Investments sold out of Stemline Therapeutics, Inc. (STML) in Q2 2017, closing a stake of 36,208 shares — an estimated $310K sold.

Oak Ridge Investments first reported a position in STML in Q3 2014 and held it in 11 quarters. The position peaked at $365K in Q4 2016. 70 funds tracked by Wall St. Rank hold STML as of Q2 2017.

  • Oak Ridge Investments reported no remaining Stemline Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Oak Ridge Investments sold 36,208 Stemline Therapeutics, Inc. shares in Q2 2017, an estimated $310K.
  • Oak Ridge Investments first reported a position in Stemline Therapeutics, Inc. in Q3 2014 and held it in 11 quarters.
  • Oak Ridge Investments's Stemline Therapeutics, Inc. position peaked at $365K in Q4 2016.
  • 70 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2017.

Based on Oak Ridge Investments's 13F filing for Q2 2017, filed 10 Aug 2017.